カテゴリ： GlobalData, アメリカ, 企業調査

Orexigen Therapeutics Inc (OREX)-製薬・医療分野：企業M&A・提携分析

◆英語タイトル：Orexigen Therapeutics Inc (OREX) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード：DATA8014385
◆発行会社（調査会社）：GlobalData
◆発行日：2017年11月22日
◆ページ数：61
◆レポート言語：英語
◆レポート形式：PDF
◆納品方法：Eメール
◆対象地域：アメリカ
◆産業分野：製薬・医療
◆販売価格オプション（消費税別）
Single UserUSD250 ⇒換算￥37,000見積依頼/購入/質問フォーム
Site License（同一事業所内共有可）USD500 ⇒換算￥74,000見積依頼/購入/質問フォーム
Enterprisewide License（複数事業所内共有可）USD750 ⇒換算￥111,000見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※本体価格が￥30,000未満のレポートにつきましては、ハンドリングチャージ￥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
※GlobalData社の概要はこちらでご確認いただけます。

このエントリーをはてなブックマークに追加
LINEで送る


【レポートの概要】

Summary
Orexigen Therapeutics Inc (Orexigen) is a biopharmaceutical company which develops and commercializes indications for the treatment of obesity. Its lead product, Contrave (naltrexone HCl / bupropion HCl prolonged release) is FDA approved as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults. Contrave is also approved in Europe under the brand name Mysimba. The company is also undertaking a range of commercialization activities, to bring Contrave / Mysimba to patients worldwide. The product is also sold in different countries worldwide through Orexigen’s partners. The company is also undertaking a range of commercialization activities, to bring Contrave / Mysimba to patients worldwide. Orexigen is headquartered in La Jolla, California, the US.

Orexigen Therapeutics Inc (OREX) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Orexigen Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Orexigen Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Orexigen Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Orexigen Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9
Orexigen Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
Orexigen Therapeutics Inc, Pharmaceuticals & Healthcare, Deal Details 12
Partnerships 12
Orexigen Therapeutics Enters into Agreement with Merck KGaA 12
Orexigen Therapeutics Enters into Distribution Agreement with CHEPLAPHARM Arzneimittel 13
Orexigen Therapeutics Enters into Distribution Agreement with Navamedic 14
Orexigen Therapeutics Enters into Distribution Agreement with Bruno Farmaceutici for Mysimba 15
Orexigen Therapeutics Enters into Distribution Agreement with Consilient Health for Mysimba 16
Orexigen Therapeutics Enters into Distribution Agreement with Valeant Pharma 17
Orexigen Therapeutics Enters into Distribution Agreement with Valeant for Contrave 18
Orexigen Therapeutics Enters into Distribution Agreement with Laboratorios Farmaceuticos Rovi 19
Orexigen Therapeutics Ireland Enters into Distribution Agreement with Kwang Dong Pharmaceutical 20
Orexigen Therapeutics Enters into Distribution Agreement with Valeant Pharma for Mysimba 21
Licensing Agreements 22
Orexigen Therapeutics Enters into Licensing Agreement with University of Bath 22
Equity Offering 23
Orexigen Therapeutics Plans to Raise up to USD20 Million in Public Offering of Shares 23
Orexigen Therapeutics Raises USD60 Million in Private Placement of Shares 24
Orexigen Therapeutics Completes Public Offering Of Common Stock For US$61 Million 25
Orexigen Therapeutics Completes Public Offering Of Units For US$90 Million 26
Debt Offering 28
Orexigen Therapeutics Raises USD165 Million in Private Placement of Notes Due 2020 28
Orexigen Therapeutics Completes Private Placement Of Notes Due 2020 For US$115 Million 29
Acquisition 30
Orexigen Therapeutics Plans to Sell Itself 30
Orexigen Therapeutics Inc – Key Competitors 31
Orexigen Therapeutics Inc – Key Employees 32
Orexigen Therapeutics Inc – Locations And Subsidiaries 33
Head Office 33
Other Locations & Subsidiaries 33
Recent Developments 34
Financial Announcements 34
Nov 13, 2017: Orexigen Therapeutics Announces Third Quarter 2017 Financial Results 34
Aug 08, 2017: Orexigen Therapeutics Announces Second Quarter 2017 Financial Results 35
May 11, 2017: Orexigen Therapeutics Reports Financial Results for the First Quarter Ended March 31, 2017 36
Mar 28, 2017: Orexigen Therapeutics Reports Financial Results for the Fourth Quarter and Year Ended December 31, 2016 37
Nov 03, 2016: Orexigen Therapeutics Reports Business and Financial Results for the Third Quarter Ended September 30, 2016 39
Aug 04, 2016: Orexigen Therapeutics Reports Business and Financial Results for the Second Quarter Ended June 30, 2016 41
May 04, 2016: Orexigen Therapeutics Reports Business and Financial Results for the First Quarter Ended March 31, 2016 42
Feb 26, 2016: Orexigen Therapeutics Reports Financial Results for the Fourth Quarter and Year Ended December 31, 2015 43
Corporate Communications 45
May 23, 2016: Orexigen Appoints New Member of Board of Directors and Announces Senior Management Changes 45
Product News 46
11/16/2016: Orexigen Announces Presentation of Data for OREX-1019, a Preclinical Candidate for the Treatment and Management of Drug Addiction 46
06/08/2016: Orexigen Therapeutics Announces Promotions of Tom Cannell to COO and Jason Keyes to CFO 47
05/27/2016: Orexigen Therapeutics Founder and Former Chairman Eckard Weber Steps Down from Board 49
05/16/2017: Orexigen Announces Activities at European Congress on Obesity 2017 51
05/03/2016: Orexigen Expands Commercial Leadership Team with Appointment of Healthcare Industry Veteran Brian Longstreet as Senior Vice President of Global Market Access and Development 52
05/02/2016: Orexigen Announces South Korean Approval of Contrave (naltrexone HCI and bupropion HCI Extended-Release) Monotherapy for Weight Management in Overweight or Obese Adult Patients 54
01/25/2017: Orexigen Therapeutics Announces Spanish Launch of Mysimba (naltrexone HCl / bupropion HCl prolonged release) in Partnership with Laboratorios Farmace´uticos Rovi 55
01/05/2017: Orexigen Therapeutics Provides Update On Contrave At 35th Annual J.P. Morgan Healthcare Conference 56
Product Approvals 58
Apr 25, 2017: Orexigen Therapeutics Announces New Drug Submission for Contrave in Canada 58
Clinical Trials 59
Jan 06, 2017: Orexigen Therapeutics Announces Publication of Contrave Real-World Study Results in “Obesity” 59
Other Significant Developments 60
Jan 11, 2016: Orexigen announces 2016 financial outlook and key priorities 60
Appendix 61
Methodology 61
About GlobalData 61
Contact Us 61
Disclaimer 61

List of Tables
Orexigen Therapeutics Inc, Pharmaceuticals & Healthcare, Key Facts, 2015 2
Orexigen Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Orexigen Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Orexigen Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Orexigen Therapeutics Inc, Deals By Therapy Area, 2011 to YTD 2017 9
Orexigen Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
Orexigen Therapeutics Enters into Agreement with Merck KGaA 12
Orexigen Therapeutics Enters into Distribution Agreement with CHEPLAPHARM Arzneimittel 13
Orexigen Therapeutics Enters into Distribution Agreement with Navamedic 14
Orexigen Therapeutics Enters into Distribution Agreement with Bruno Farmaceutici for Mysimba 15
Orexigen Therapeutics Enters into Distribution Agreement with Consilient Health for Mysimba 16
Orexigen Therapeutics Enters into Distribution Agreement with Valeant Pharma 17
Orexigen Therapeutics Enters into Distribution Agreement with Valeant for Contrave 18
Orexigen Therapeutics Enters into Distribution Agreement with Laboratorios Farmaceuticos Rovi 19
Orexigen Therapeutics Ireland Enters into Distribution Agreement with Kwang Dong Pharmaceutical 20
Orexigen Therapeutics Enters into Distribution Agreement with Valeant Pharma for Mysimba 21
Orexigen Therapeutics Enters into Licensing Agreement with University of Bath 22
Orexigen Therapeutics Plans to Raise up to USD20 Million in Public Offering of Shares 23
Orexigen Therapeutics Raises USD60 Million in Private Placement of Shares 24
Orexigen Therapeutics Completes Public Offering Of Common Stock For US$61 Million 25
Orexigen Therapeutics Completes Public Offering Of Units For US$90 Million 26
Orexigen Therapeutics Raises USD165 Million in Private Placement of Notes Due 2020 28
Orexigen Therapeutics Completes Private Placement Of Notes Due 2020 For US$115 Million 29
Orexigen Therapeutics Plans to Sell Itself 30
Orexigen Therapeutics Inc, Key Competitors 31
Orexigen Therapeutics Inc, Key Employees 32
Orexigen Therapeutics Inc, Subsidiaries 33

★海外企業調査レポート[Orexigen Therapeutics Inc (OREX)-製薬・医療分野：企業M&A・提携分析]についてメールでお問い合わせはこちら
■おすすめ企業レポート■
  • United Food Holdings Limited：企業の戦略・SWOT・財務分析
    United Food Holdings Limited - Strategy, SWOT and Corporate Finance Report Summary United Food Holdings Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and s …
  • BroadSoft Inc.：企業のM&A・事業提携・投資動向
    BroadSoft Inc. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's BroadSoft Inc. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestmen …
  • Cue Health Inc：企業の製品パイプライン分析2018
    Summary Cue Health Inc (Cue Health) is a healthcare technology company that strives to design, develop, manufacture and commercialize medical diagnostic products for use in home and clinical settings. The company’s lead product, Cue Health Monitoring System, is a connected diagnostic platform that h …
  • Bayer AG (BAYN)-医療機器分野：企業M&A・提携分析
    Summary Bayer AG (Bayer) carries out the research, development, production and commercialization of products in the areas of human and animal health care, and agriculture. It provides pharmaceuticals for cardiology, women’s healthcare, oncology, hematology, ophthalmology, infection and other indicat …
  • The Bank of Kochi, Ltd.：企業の戦略・SWOT・財務情報
    The Bank of Kochi, Ltd. - Strategy, SWOT and Corporate Finance Report Summary The Bank of Kochi, Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • Frequency Therapeutics Inc：製薬・医療：M&Aディール及び事業提携情報
    Summary Frequency Therapeutics Inc (Frequency Therapeutics) is a biotechnology company that develops progenitor cell activation (PCA) therapies. The company’s small molecule drugs are used to activate progenitor cells for restoration of healthy tissue. Its lead program FX-322 is used to recreate sen …
  • Electro Scientific Industries Inc (ESIO)：企業の財務・戦略的SWOT分析
    Summary Electro Scientific Industries Inc (ESI) is a technology company that offers laser-based manufacturing solutions. The company offers products such as flex interconnect, circuit packaging, high density interconnect, automation, scribbing and grooving, memory repair, wafer marking, laser ablati …
  • Milliken & Company：戦略・SWOT・企業財務分析
    Milliken & Company - Strategy, SWOT and Corporate Finance Report Summary Milliken & Company - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • Senvion SA：企業の戦略的SWOT分析
    Senvion SA - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. T …
  • Avnet, Inc (AVT)：企業の戦略的SWOT分析
    Avnet, Inc (AVT) - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and servi …
  • National Reinsurance Corporation Of The Philippines
    National Reinsurance Corporation Of The Philippines - Strategy, SWOT and Corporate Finance Report Summary National Reinsurance Corporation Of The Philippines - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's stru …
  • Dynegy Inc：発電所・企業SWOT分析
    Dynegy Inc - Power Plants and SWOT Analysis, 2017 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, information on key employees (executi …
  • Piraeus Bank SA：企業のM&A・事業提携・投資動向
    Piraeus Bank SA - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Piraeus Bank SA Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestm …
  • Valeant Pharmaceuticals International, Inc.：企業の戦略・SWOT・財務情報
    Valeant Pharmaceuticals International, Inc. - Strategy, SWOT and Corporate Finance Report Summary Valeant Pharmaceuticals International, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation …
  • HSH Nordbank AG：企業のM&A・事業提携・投資動向
    HSH Nordbank AG - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's HSH Nordbank AG Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestm …
  • General Electric Co (GE)：企業の財務・戦略的SWOT分析
    General Electric Co (GE) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • Cydan Development Inc：製薬・医療：M&Aディール及び事業提携情報
    Summary Cydan Development Inc (Cydan) is an orphan drug accelerator dedicated to advancing therapies for rare genetic diseases. The company identifies assets with biology and proof-of-concept data in vivo models from academic circles, industry, and other sources. It offers various technology platfor …
  • Nido Petroleum Ltd：企業の戦略的SWOT分析
    Nido Petroleum Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and ser …
  • InterGen：企業の戦略的SWOT分析
    InterGen - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. Thi …
  • Micron Technology Inc：企業の戦略・SWOT・財務分析
    Micron Technology Inc - Strategy, SWOT and Corporate Finance Report Summary Micron Technology Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …

◆H&Iグローバルリサーチ株式会社のお客様（例）◆